.png)
If your organization participates in the 340B Drug Pricing Program as a federal grantee, you already know the benefit: the ability to purchase outpatient drugs at significantly reduced prices, generating revenue that can be reinvested into patient care. What is less often discussed at the leadership level is how quickly that benefit can become a liability when compliance breaks down.
This article walks through the three compliance areas that generate the most significant exposure for 340B federal grantees, and explains what your organization should have in place to manage each one.
To use a 340B acquisition price on a drug, your organization must first establish that the patient receiving that drug is a qualifying 340B patient. HRSA’s patient definition requires three things: the individual has an established care relationship with your organization, your organization holds responsibility for their care, and that care is documented in your medical records.
For federal grantees, there is a fourth layer that hospitals do not face: the patient’s visit must fall within the approved scope of your federal grant. This is where most grantee compliance programs have gaps.
At first glance, patient eligibility seems straightforward: confirm an established relationship, confirm care responsibility, confirm documentation, and move forward.
For federal grantees, however, eligibility does not stop at the HRSA patient definition. It must also align with the approved scope of the federal grant.
Organizations with strong compliance in this area have done two things. First, they have clearly documented their grant’s approved scope of care and trained clinical and front-desk staff to understand which visit types fall within it. Second, they have configured their pharmacy system or third-party administrator’s logic to flag or exclude prescriptions that originate from out-of-scope encounters before a 340B claim is generated.
The warning signs to watch for: patients flagged as 340B-eligible for visits outside your grant’s scope of project, dispensing systems that qualify patients based on relationship alone without a grant-scope check, no documented policy defining which encounter types qualify under your specific grant, and staff uncertainty about what your grant’s approved scope of care actually covers.
Most federal grantees do not operate their own in-house pharmacy. Instead, they partner with one or more retail or specialty pharmacies under a formal contract pharmacy arrangement. Under this model, a patient presents at the contract pharmacy with a prescription written by a provider at your covered entity. The pharmacy dispenses the drug, and your organization is credited for the 340B discount through a replenishment or claims-based process.
In recent years, a number of drug manufacturers have placed restrictions on how many contract pharmacies a covered entity can designate for their drugs. For larger health systems with in-house pharmacies, this is a manageable inconvenience. For grantees who have no in-house option and rely entirely on contract pharmacy arrangements to access 340B pricing, these restrictions can cut off access to discounted pricing on specific drugs entirely.
This is an active and evolving area, litigation is ongoing and federal guidance continues to develop, but the operational impact is real today. Grantees should understand which manufacturers have imposed restrictions, how those restrictions affect their formulary, and what their options are if a primary contract pharmacy relationship is disrupted.
Every contract pharmacy relationship should be covered by a written agreement that is registered in HRSA’s 340B OPAIS database before dispensing begins. Beyond registration, your organization should conduct regular reviews of TPA performance data to confirm that 340B claims are being generated only for qualifying patients, that the replenishment model is functioning correctly, and that the pharmacy is not creating duplicate discount exposure on your behalf. Audit rights language in your contract pharmacy agreement is not optional, it is your primary mechanism for accountability.
The 340B Office of Pharmacy Affairs Information System, known as OPAIS, is the federal database where covered entities register and maintain their 340B program information. Every location where 340B drugs are prescribed or dispensed, including your main site, any off-site outpatient locations, and every contract pharmacy, must be registered in OPAIS and kept current.
If a site is not registered in OPAIS, 340B drugs cannot lawfully be used there. If a site carries outdated information, a wrong address, a provider list that no longer reflects current staff, a contract pharmacy that has changed ownership, your program is exposed. HRSA auditors cross-reference OPAIS registration data against actual operations as a standard part of every audit.
OPAIS accuracy problems typically develop gradually. A clinic opens a satellite location and begins seeing patients there, with the intention of registering it soon. A contract pharmacy changes its name following an acquisition but no one updates the registration. A provider leaves the organization and TPA adjustments are not made to reflect this, therefore claims are still being generated under their credentials. None of these feel like significant events in the moment, but each one creates a compliance gap that is visible to auditors and difficult to explain after the fact.
For grantees specifically, OPAIS registration must also reflect your current grant status. If your grant has been renewed, modified, or amended, your OPAIS record should reflect the current Notice of Award information. A mismatch between your grant documentation and your OPAIS registration is a straightforward audit finding that is entirely avoidable.
Strong programs treat OPAIS as a living record, not a one-time registration task. This means designating a staff member with ownership of OPAIS accuracy, building registration review into the onboarding process for new sites and providers, and conducting a formal annual reconciliation of your OPAIS record against your actual operations, grant documentation, and contract pharmacy agreements.
Across all three risk areas, the pattern is the same: compliance gaps rarely appear overnight. They accumulate gradually, through staff turnover, operational growth, system changes, and the day-to-day press of running a healthcare organization. By the time an audit surfaces them, they can represent months or years of exposure.
These are manageable risks. Patient eligibility policies, contract pharmacy oversight frameworks, and OPAIS maintenance protocols are not complex to design, but they do require organizational ownership and consistent follow-through. For executives, the right question to ask is not “are we compliant?” but “Could we prove it if we were audited tomorrow?”
